RECRUITING

Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to test if visualizing the heart with cardiac MRI/echo will be important in the understanding cardiac function and prediction of cardiopulmonary symptoms, physical effort tolerance, and outcomes in COVID-19 survivors. If successful, the research will allow us to identify the causes of lasting cardiopulmonary symptoms and begin developing cardiac and lung directed therapies accordingly.

Official Title

Cardiac Magnetic Resonance for Tissue Characterization-Based Risk Stratification of Cardiopulmonary Symptoms, Effort Tolerance, and Prognosis Among COVID-19 Survivors

Quick Facts

Study Start:2021-07-01
Study Completion:2026-07-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05164744

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Emergency room presentation and/or hospitalization with COVID-19 infection defined in accordance with established criteria as follows: SAR-CoV2 RT-PCR+ (severe acute respiratory syndrome coronavirus 2 reverse transcription polymerase chain reaction) and at least one of the following symptoms: dyspnea, cough, dysphagia, rhinorrhea, diarrhea, nausea/vomiting, myalgias, fever, syncope/presyncope.
  1. * Contraindication to CMR (i.e. non-compatible pacemaker/defibrillator) or gadolinium (known hypersensitivity, eGFR (estimated globular filtration rate) \<30 ml/min/1.73m2).
  2. * Inability to provide informed consent (e.g. cognitive impairment).
  3. * Unrelated condition (e.g. neoplasm) with life expectancy \<12 months prohibiting follow-up.
  4. * Patients with contraindications to gadolinium (known or suspected hypersensitivity, glomerular filtration rate \< 30 ml/min/1.73m2) will undergo non-contrast MRI but will not be excluded from this study.
  5. * Patients with known or suspected pregnancy based on Weill Cornell Radiology intake surveys (reviewed by a clinical RN (registered nurse), as well as research personnel) will be excluded from the protocol.

Contacts and Locations

Study Contact

Caitlin Chiu, BA
CONTACT
2127462627
CovidHeartStudy@med.cornell.edu
Mahniz Reza, BA
CONTACT
2127462627
CovidHeartStudy@med.cornell.edu

Principal Investigator

Jiwon Kim, MD
PRINCIPAL_INVESTIGATOR
Weill Medical College of Cornell University

Study Locations (Sites)

New York Presbyterian-Brooklyn Methodist Hospital
Brooklyn, New York, 11215-3609
United States
New York Presbyterian Queens
New York, New York, 10021
United States
Weill Cornell Medicine/New-York Presbyterian Hospital
New York, New York, 10021
United States

Collaborators and Investigators

Sponsor: Weill Medical College of Cornell University

  • Jiwon Kim, MD, PRINCIPAL_INVESTIGATOR, Weill Medical College of Cornell University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-07-01
Study Completion Date2026-07-30

Study Record Updates

Study Start Date2021-07-01
Study Completion Date2026-07-30

Terms related to this study

Keywords Provided by Researchers

  • coronavirus disease 2019,

Additional Relevant MeSH Terms

  • COVID-19 Pneumonia
  • COVID-19
  • COVID-19 Respiratory Infection
  • COVID-19 Acute Respiratory Distress Syndrome
  • COVID-19 Lower Respiratory Infection
  • COVID-19 Acute Bronchitis
  • Coronavirus Disease 2019